SCHEMBL3520216

SCHEMBL3520216

CC1(C)C(=O)Nc2ccc(-c3cccc(C#N)c3F)cc21

nearest known ligand 0.60

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PGR P06401 16/20 0.60
PDE3B Q13370 4/20 0.45
PDE3A Q14432 4/20 0.45
PDE4A P27815 3/20 0.44
PDE4B Q07343 3/20 0.44
PDE4C Q08493 3/20 0.44
PDE4D Q08499 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4175084 0.82 PGR (0.68) PGR
SCHEMBL4319274 0.78 PGR (0.73) PGR
SCHEMBL3518135 0.76 PGR (1.00) PGRPDE3BPDE3A
SCHEMBL3526703 0.72 PGR (1.00) PGR
SCHEMBL1223269 0.72 PGR (0.67) PGR
SCHEMBL9957825 0.71 PDK2 (0.47) PGR
SCHEMBL16858523 0.70 PGR (0.55) PGRPDE3BPDE3A
SCHEMBL25944404 0.70 PGR (0.71) PGRPDE3BPDE3APDE4APDE4B
SCHEMBL7157408 0.69 PGR (0.64) PGR
SCHEMBL20373743 0.69 USP30 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1175398-B1 INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS WYETH CORP (US) 2007-07-11 EP claimed
US-7084168-B2 Indoline derivatives WYETH (US) 2006-08-01 US claimed
US-20030220388-A1 Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents WYETH 2003-11-27 US claimed
US-6544970-B2 Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative WYETH 2003-04-08 US claimed
US-20030050288-A1 Cyclic regimens utilizing indoline derivatives WYETH 2003-03-13 US claimed
JP-2002543183-A 2002-12-17 JP claimed
JP-2002543158-A 2002-12-17 JP claimed
US-6462032-B1 Cyclic regimens utilizing indoline derivatives WYETH 2002-10-08 US claimed
US-20020086874-A1 Indoline derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 2002-07-04 US claimed
CN-1350523-A Indoline derivatives as progesterone antagonists AMERICAN HOME PROD (US) 2002-05-22 CN claimed
CN-1349416-A Contraceptive compositions contaiing indoline derivatives and progestational agents AMERICAN HOME PROD (US) 2002-05-15 CN claimed
EP-1175398-A1 INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS American Home Products Corporation (US) 2002-01-30 EP claimed
EP-1173212-A1 CONTRACEPTIVE COMPOSITIONS CONTANING INDOLONE DERIVATIVES AND PROGESTATIONAL AGENTS American Home Products Corporation (US) 2002-01-23 EP claimed
WO-2000066167-A1 CONTRACEPTIVE COMPOSITIONS CONTAINING INDOLINE DERIVATIVES AND PROGESTATIONAL AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO claimed
WO-2000066556-A1 INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO claimed
US-7645761-B2 Indoline derivatives WYETH (US) 2010-01-12 US disclosed
US-20070259944-A1 Indoline derivatives WYETH (US) 2007-11-08 US disclosed
EP-1173212-A1 CONTRACEPTIVE COMPOSITIONS CONTANING INDOLONE DERIVATIVES AND PROGESTATIONAL AGENTS American Home Products Corporation (US) 2002-01-23 EP disclosed
WO-2000066167-A1 CONTRACEPTIVE COMPOSITIONS CONTAINING INDOLINE DERIVATIVES AND PROGESTATIONAL AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO disclosed
WO-2000066556-A1 INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259944-A1 Indoline derivatives PGR, GNRHR, PRLHR PGR 1/4885PDE3B 2186/4885PDE3A 2148/4885
US-20020086874-A1 Indoline derivatives PGR, GNRHR, PRLHR PGR 1/4885PDE3B 2875/4885PDE3A 2632/4885
US-20030220388-A1 Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents PGR, CYP19A1, PGRMC1 PGR 1/4885PDE3B 1951/4885PDE3A 1588/4885
US-20030050288-A1 Cyclic regimens utilizing indoline derivatives PRLHR, GNRHR, BRCA1 PGR 5/4885PDE3B 684/4885PDE3A 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.